Trial record 1 of 1 for:
NCT01472562
Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01472562 |
|
Recruitment Status :
Active, not recruiting
First Posted : November 16, 2011
Results First Posted : April 7, 2017
Last Update Posted : February 28, 2023
|
Sponsor:
Weill Medical College of Cornell University
Collaborator:
Celgene
Information provided by (Responsible Party):
Weill Medical College of Cornell University
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a phase II, multicenter study to determine the efficacy and safety of first-line lenalidomide plus rituximab therapy in patients with mantle cell lymphoma who have received no prior systemic therapy.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Mantle Cell Lymphoma | Drug: lenalidomide Biological: rituximab | Phase 2 |
Induction Phase (week 1 - 48):
- Lenalidomide will be given at 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.
- Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44.
Maintenance Phase (week 49 - progression of disease):
- Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle.
- Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52.
Response Assessment
- Year 1-2: Conventional restaging CT scan (or MRI) with IV contrast every 3 months from cycle 1 day 1 of the study.
- Year 3 onwards: Conventional restaging CT scan (or MRI) with IV contrast every 6 months until progression.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 38 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Phase II Study of Lenalidomide Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma |
| Actual Study Start Date : | July 29, 2011 |
| Actual Primary Completion Date : | April 2014 |
| Estimated Study Completion Date : | June 30, 2023 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: all patients
Induction Phase (week 1 - 48):
Maintenance Phase (week 49 - progression of disease):
|
Drug: lenalidomide
Induction phase: 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day. Maintenance phase: Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle. Other Name: revlimid Biological: rituximab Induction phase: Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44. Maintenance phase: Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52. Other Name: rituxan |
Primary Outcome Measures :
- Overall Response Rate [ Time Frame: 30 months ]The primary endpoint of overall response rate will be estimated and a 95% confidence interval will be estimated via binomial proportions.
Secondary Outcome Measures :
- Progression-free Survival [ Time Frame: 10 years ]PFS will be defined as the time from first treatment day until objective or symptomatic progression or death.
- Overall Survival [ Time Frame: 10 years ]Overall survival will be defined as the time from first treatment day until death.
- Time to Next Treatment [ Time Frame: 10 years ]Median amount of time (in months) from start of study treatment to next treatment
- Safety as Measured by Number of Subjects Who Experience an Adverse Event While on Study Treatment [ Time Frame: 10 years ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Understand and voluntarily sign an informed consent form.
- Age > = 18 years at the time of signing the informed consent form.
- Able to adhere to the study visit schedule and other protocol requirements.
- Histologically confirmed diagnosis of mantle cell Non-Hodgkin's Lymphoma with cyclin D1 overexpression by immunohistochemistry, and a characteristic immunophenotypic profile with CD5(+), CD23(-), CD20(+), and CD10(-). In tumor tissues with negative cyclin D1, evidence of cyclin D2 or D3 overexpression by immunohistochemistry will be acceptable.
- No prior systemic therapy for lymphoma including chemotherapy or immunotherapy. Patients may have received involved-field radiation therapy which has been discontinued at least 4 weeks prior to treatment in this study.
- Patient has measurable disease as defined by a tumor mass > 1.5 cm in one dimension.
- Low and intermediate-risk disease as defined by MIPI score.
- Subject who the investigator considers that chemotherapy is not indicated.
- ECOG performance status of < = 2 at study entry.
-
Laboratory test results within these ranges:
- Absolute neutrophil count > = 1000 /mm³
- Platelet count > = 75,000 /mm³
- Calculated creatinine clearance ≥ 30 ml/min by Cockcroft-Gault formula • Total bilirubin < = 2 x ULN
- AST (SGOT) and ALT (SGPT) < = 3 x ULN.
- Disease free of prior malignancies for > = 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, carcinoma "in situ" of the cervix or breast, or localized prostate cancer.
- All subjects must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.
- Subjects of reproductive potential agree to use birth control throughout their participation in this study, and for three months following study termination.
- Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days and again within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days). FCBP must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. See Appendix: Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods.
- Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin).
- Asymptomatic carriers of hepatitis B virus can be considered for study if they agree to and comply with close monitoring and suppressive therapy with lamivudine during treatment and for additional six months after coming off study.
Exclusion Criteria:
- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- Pregnant or breast feeding females.
- Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- Use of any other experimental drug or therapy within 28 days of baseline.
- Patient on corticosteroids within two weeks prior to study entry, except for prednisone < = 10 mg/day or equivalent for purposes other than treating MCL.
- Known hypersensitivity to thalidomide.
- Any prior use of lenalidomide.
- Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.
- Known central nervous system (CNS) involvement by lymphoma.
- Patient at high risk for deep vein thrombosis not willing to take DVT prophylaxis.
- Patient has had major surgery within the last 3 weeks
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01472562
Locations
| United States, Florida | |
| Moffitt Cancer Center | |
| Tampa, Florida, United States, 33612 | |
| United States, Illinois | |
| University of Chicago | |
| Chicago, Illinois, United States, 60637 | |
| United States, New York | |
| Weill Cornell Medical College | |
| New York, New York, United States, 10065 | |
| United States, Pennsylvania | |
| University of Pennsylvania | |
| Philadelphia, Pennsylvania, United States, 19104 | |
Sponsors and Collaborators
Weill Medical College of Cornell University
Celgene
Investigators
| Principal Investigator: | Jia Ruan, MD, PhD | Weill Medical College of Cornell University |
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Weill Medical College of Cornell University |
| ClinicalTrials.gov Identifier: | NCT01472562 |
| Other Study ID Numbers: |
1103011566 |
| First Posted: | November 16, 2011 Key Record Dates |
| Results First Posted: | April 7, 2017 |
| Last Update Posted: | February 28, 2023 |
| Last Verified: | January 2023 |
Keywords provided by Weill Medical College of Cornell University:
|
mantle cell lymphoma |
Additional relevant MeSH terms:
|
Lymphoma Lymphoma, Mantle-Cell Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin Rituximab |
Lenalidomide Antineoplastic Agents, Immunological Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Growth Inhibitors |